Glaucoma drug compliance linked to age

Article

Glaucoma medication compliance and effectiveness of drug administration correlates with age and severity of disease.

Glaucoma medication compliance and effectiveness of drug administration correlates with age and severity of disease, according to a report presented at the annual meeting of the French Society of Ophthalmology.

Florent Aptel, MD and colleagues asked patients to complete a questionnaire concerning non-observance of treatment schedules. In addition, visual field examinations were performed and patients were asked to apply eye drops in the same way as they would at home.

Twenty-four percent of patients admitted non-compliance and approximately 20% instilled their drops outside of the eye. The non-compliant patients were mainly younger or those with earlier stages of the disease. Those who had difficulty in applying the drops tended to be older, with poorer visual acuity and larger visual field defects.

Based on this data the researchers identified two typical patient groups. The first are the relatively young patients with early stage glaucoma, which does not have a significant impact on their life. These subjects are able to carry out the instillation properly but are likely to be less compliant. The second group comprises of the older patients who have more advanced glaucoma, which does have a significant impact on their day-to-day life. These are more compliant but have difficulties performing the instillation correctly, often allowing all or part of the medication to drop outside of the eye.

This study suggests that compliance and drug administration in glaucoma patients can be directly correlated to age and disease severity.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.